Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2010)
12 slides from Terumo's investor presentation, May 12, 2010
Slide 1: World-class company that leads Japan's healthcare industry
World-class company that leads Japan’s healthcare industry Yutaro Shintaku Director and Managing Executive Officer Strategy Planning Dept. Terumo Corporation May 12, 2010 1/12
Slide 2: Significant shift in business environment
Significant shift in business environment Rising healthcare demands in China, Asia, other emerging economies - Rapid development of healthcare infrastructure Healthcare reforms in US and EU - Increasing focus on healthcare economy Growing expectation in Japan as a strategic industry for economic
Slide 3: Terumo's new directions for growth
Terumo’s new directions for growth Cardiac and Other vascular businesses CAGR EU / US 15% in the last 5yrs China / Asia / Others 3/12
Slide 4: Enhanced global management
Enhanced global management Management led by associates’ individual initiatives Development of global leaders Infrastructure for better management ： SCM/IT ... Speed and Global Perspective 4/12
Slide 5: Pursuit of new growth opportunities
Pursuit of new growth opportunities ① Value added drug delivery devices catered for biomedicine ② Global diabetes management business ③ Transfusion as a basic healthcare infrastructure ④ Further expansion of the minimally invasive procedures ⑤ Growth of Left Ventricular Assist Device driven by desti
Slide 6: Value added drug delivery devices catered for biomedicine
Pursuit of new growth opportunities ① Value added drug delivery devices catered for biomedicine Current Future Synthetic Medicine Biomedicine Oral administration Injection Biomedicine market $120 billion⇒$200 billion in ten years Growing demands of value added drug delivery device catered for biomed
Slide 7: Global diabetes management business
Pursuit of new growth opportunities ② Global diabetes management business Diabetics undergoing blood glucose control: - Number is expected to triple or quadruple world-wide - China, Asia and other emerging markets outgrow developed countries Diabetes related complications lower quality of life and u
Slide 8: Transfusion as a basic healthcare infrastructure
Pursuit of new growth opportunities ③ Transfusion as a basic healthcare infrastructure Developed countries: Needs of efficient blood processing Emerging countries: Buildup of blood supply system -WHO estimate of minimally needed number of donation, 1% of population, will be reached -Number of dona
Slide 9: Further expansion of minimally invasive procedures
Pursuit of new growth opportunities ④ Further expansion of minimally invasive procedures Application of catheter technologies -Coronary ⇒ Neuro, peripheral and orthopedic etc. -Japanese refined manufacturing and high quality Shift towards minimally invasive surgical procedures -Open surgery ⇒ Robo
Slide 10: Growth of Left Ventricular Assist Device driven by destination therapy
Pursuit of new growth opportunities ⑤Growth of Left Ventricular Assist Device driven by destination therapy Bridge to transplant Market size: $200 million ～ Reduced size & +Destination therapy Higher reliability Market size of $2 billion in 2020 ＋Bridge to recovery Market size of $5 billion after 20
Slide 11: World-class company that leads Japan's healthcare industry
World-class company that leads Japan’s healthcare industry Exceed sales of ¥1 trillion by 2020 11/12
Slide 12: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: kouhou_terumo01@terumo.co.jp Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo